Prostate cancer treatment can involve several different approaches, depending on the cancer's stage, Grade Group, PSA level, whether it has spread, overall health, and other individual factors. Treatment may range from careful monitoring for some localized cancers to surgery, radiation, hormone therapy, chemotherapy, targeted therapy, or combinations of treatments for more advanced disease.
The prostate is a gland in the male reproductive system located below the bladder and in front of the rectum. Prostate cancer develops when abnormal cells in the prostate grow uncontrollably.
Many prostate cancers grow slowly, while some can grow more quickly and spread beyond the prostate. Determining how aggressive the cancer is and whether it has spread is an important part of treatment planning.
Doctors use several types of information to diagnose and evaluate prostate cancer.
Common evaluations can include:
A biopsy can confirm the presence of cancer and provide information about the cancer's Grade Group, which is based on the Gleason score.
PSA, or prostate-specific antigen, is a protein produced by prostate cells.
A PSA test measures the amount of PSA in the blood. Elevated PSA can occur for several reasons and does not by itself establish a diagnosis of prostate cancer.
For people already diagnosed with prostate cancer, PSA can also be used to help assess risk and monitor the disease during and after treatment.
Doctors interpret PSA alongside biopsy findings, examination results, imaging, and other clinical information.
The Gleason scoring system evaluates how prostate cancer cells appear under a microscope.
The resulting Grade Group helps indicate how likely the cancer is to grow and spread.
Treatment decisions generally consider Grade Group together with PSA, tumor extent, imaging, biopsy findings, and other factors rather than relying on one measurement alone.
Prostate cancer is generally categorized from stage I through stage IV.
Staging considers:
Stage I generally represents cancer with limited extent and favorable characteristics, while stage IV indicates more advanced disease. Stage IV can include cancer involving nearby lymph nodes or cancer that has spread to distant locations.
The stage and risk classification help the cancer-care team determine which treatments may be appropriate.
For localized prostate cancer, doctors may also assign a risk category such as very low, low, intermediate, high, or very high risk.
Other factors can influence treatment decisions, including age, overall health, life expectancy, personal circumstances, and potential treatment side effects.
Active surveillance is an approach used for certain prostate cancers that have a relatively low risk of progressing.
Instead of treating the cancer immediately, the healthcare team monitors it through scheduled testing and examinations.
Monitoring may include:
If evidence indicates that the cancer is becoming more aggressive, active treatment can then be considered.
For very low- and low-risk prostate cancers, active surveillance is commonly considered because immediate treatment may expose some patients to treatment-related side effects without providing a clear additional benefit.
Observation is different from active surveillance.
Active surveillance generally involves closer monitoring with the intention of starting treatment if the cancer shows signs of progression.
Observation or watchful waiting may instead focus on managing symptoms and maintaining quality of life, particularly when other health conditions or life expectancy make intensive cancer treatment less appropriate.
The distinction should be discussed with the treating physician.
Radical prostatectomy is a surgical procedure that removes the prostate and surrounding tissues, including the seminal vesicles.
Nearby lymph nodes may also be removed in selected circumstances.
Surgery can be considered for certain men whose cancer is confined to or primarily localized around the prostate.
After surgery, pathology results can provide additional information about the cancer and may influence whether further treatment is recommended.
Potential effects of prostate surgery can include:
The likelihood and severity of side effects vary among individuals and can depend on factors such as the surgical approach, tumor characteristics, baseline health, and experience of the treatment team.
Radiation therapy uses high-energy radiation to damage and destroy cancer cells.
Two major approaches include:
Radiation is delivered from a machine outside the body.
Different radiation techniques may be used depending on the cancer and treatment center.
Brachytherapy places radioactive material inside or near the prostate.
It may be used alone for selected localized cancers or combined with external radiation for certain higher-risk cancers.
Radiation can also be used in some situations when prostate cancer has spread or returned.
Side effects can vary according to the treatment technique and area being treated.
Possible effects include:
Some side effects occur during treatment, while others can develop later.
Hormone therapy, also called androgen-deprivation therapy, reduces or blocks the effects of male hormones that can stimulate prostate cancer growth.
It can be used alone in certain situations or combined with radiation and other cancer treatments.
For higher-risk or advanced prostate cancer, newer hormone-targeting medicines may be added to treatment.
Hormone therapy can produce effects related to reduced androgen activity.
Potential side effects include:
Doctors may monitor bone health, cardiovascular risk factors, and other health measures during longer-term hormone treatment.
Chemotherapy uses medicines that destroy or inhibit rapidly dividing cancer cells.
It may be considered for certain advanced or metastatic prostate cancers, often in combination with hormone-based treatment.
Docetaxel is one chemotherapy medicine used in prostate cancer treatment.
The specific treatment combination depends on the cancer's characteristics and previous treatments.
Targeted therapies are designed to interfere with specific biological features involved in cancer growth.
Certain targeted treatments may be appropriate when testing identifies particular genetic or molecular changes in the cancer.
For example, some metastatic prostate cancers with specific DNA-repair abnormalities may be candidates for PARP-inhibitor treatment.
Molecular testing can therefore play an important role in treatment planning for selected advanced cancers.
Immunotherapy uses medicines that help the immune system recognize or attack cancer cells.
It is not appropriate for every person with prostate cancer.
Certain immunotherapy approaches may be considered for selected advanced cancers based on specific characteristics of the tumor and previous treatment.
Metastatic prostate cancer has spread beyond the prostate to distant parts of the body.
Common treatment approaches can include combinations involving:
For metastatic disease, treatment commonly focuses on controlling cancer, slowing progression, relieving symptoms, and maintaining quality of life.
Prostate cancer can sometimes return after initial treatment.
This is called recurrent prostate cancer.
Recurrence may be identified through:
Treatment depends on the original treatment, location of recurrence, PSA behavior, previous therapies, and overall health.
Potential approaches can include additional radiation, hormone therapy, surgery in selected circumstances, systemic medicines, or clinical trials.
Treatment options differ substantially between risk categories.
Active surveillance is commonly considered.
Other possibilities can include surgery or radiation for selected patients.
Depending on individual circumstances, options can include:
Treatment may include surgery or radiation combined with hormone therapy.
Treatment can involve combinations of radiation and hormone therapy or surgery in selected patients.
Advanced metastatic cancer is generally treated with systemic therapies, which may be combined with radiation or other treatments depending on the circumstances.
There is no single treatment that is appropriate for every prostate cancer diagnosis.
Doctors may consider:
For localized prostate cancer, the decision can involve balancing cancer-control goals with possible effects on urinary, bowel, and sexual function.
Side effects depend heavily on the treatment.
Possible effects include urinary incontinence and erectile dysfunction.
Potential effects include urinary, bowel, sexual, and fatigue-related symptoms.
Possible effects include hot flashes, sexual changes, fatigue, bone-density changes, and metabolic effects.
Possible effects can include fatigue, nausea, changes in blood-cell counts, infection risk, and other medicine-specific effects.
The healthcare team can explain which effects are most relevant to a particular treatment plan.
Supportive care can help manage many treatment-related effects.
Depending on the situation, care may include:
Patients should report new or worsening symptoms to the cancer-care team rather than attempting to manage serious treatment effects independently.
Clinical trials evaluate new treatments and new combinations of existing treatments.
Trials may investigate:
The National Cancer Institute provides information about clinical trials for prostate cancer.
Eligibility depends on factors such as cancer stage, previous treatment, genetic characteristics, age, general health, and other study-specific criteria.
Treatment can involve multiple specialists.
Common members include:
The American Cancer Society notes that different specialists may work together depending on the patient's treatment needs.
Before making a treatment decision, useful questions can include:
| Treatment | Common Role | Key Considerations |
|---|---|---|
| Active surveillance | Selected low-risk cancers | Requires ongoing monitoring |
| Surgery | Selected localized cancers | Can affect urinary and sexual function |
| Radiation therapy | Localized and some advanced cancers | Treatment schedule and side effects vary |
| Hormone therapy | Intermediate/high-risk and advanced disease | Can cause systemic hormonal effects |
| Chemotherapy | Selected advanced cancers | Medicine-specific side effects |
| Targeted therapy | Selected cancers with relevant molecular features | Requires appropriate tumor characteristics |
| Immunotherapy | Selected advanced cancers | Eligibility depends on cancer characteristics |
| Clinical trials | Various stages | Investigates newer approaches |
A second medical opinion can provide additional information about diagnosis, staging, and treatment possibilities.
It may be particularly useful when:
Medical records, biopsy slides, imaging, and laboratory results may be needed for a comprehensive second opinion.
Patients can prepare by bringing:
Writing down questions in advance can make a consultation easier to follow.
It can also be useful to bring a family member or support person, if permitted and desired.
When reviewing a diagnosis, consider:
PSA level
Biopsy results
Gleason score
Grade Group
Cancer stage
Imaging results
Risk group
Whether cancer has spread
Treatment goals
Available treatment approaches
Potential side effects
Follow-up requirements
Clinical-trial eligibility
Second-opinion considerations
Treatment depends on the cancer's stage and risk characteristics. Possible approaches include active surveillance, surgery, radiation therapy, hormone therapy, chemotherapy, targeted therapy, immunotherapy, and clinical trials.
For selected very low- and low-risk cancers, active surveillance is commonly used. The cancer is monitored and treatment can begin if there are signs of progression.
No. Surgery is one possible treatment for selected patients, but radiation, active surveillance, and other approaches may also be considered depending on the cancer's characteristics.
Treatment generally focuses on controlling the cancer and managing symptoms. Depending on the disease, treatment can include hormone therapy, newer hormone medicines, chemotherapy, targeted therapy, radiation, and other approaches.
Yes. Recurrence can occur after treatment, and a rising PSA can be one indication of recurrence. The subsequent treatment depends on where and how the cancer has returned and what treatment was previously given.
Yes. Clinical trials continue to evaluate new medicines, treatment combinations, radiation approaches, and other therapies.
Prostate cancer treatment depends on the stage, Grade Group, PSA level, risk classification, spread of disease, overall health, and individual treatment considerations.
For some lower-risk cancers, active surveillance can be appropriate. Other localized cancers may be treated with surgery or radiation. Higher-risk and metastatic cancers may require combinations of radiation, hormone therapy, chemotherapy, targeted medicines, or other systemic treatments.